The $130M Bet on the Migraine Patients That Nobody Can Help

Slate is fishing in a different pond entirely.

Their target is PACAP (pituitary adenylate cyclase-activating polypeptide). Don't worry about the name. What matters is that PACAP drives migraine through pathways that are completely independent of CGRP. Scientists have proven this in knockout mice that can't respond to CGRP at all. Give those mice PACAP, and they still develop migraine-like symptoms. Block CGRP with antibodies in normal mice, then hit them with PACAP; same result.

Think of it like this: if CGRP is one road leading to Migraine City, PACAP is a totally separate highway. Blocking one road doesn't stop traffic on the other.

When researchers injected PACAP-38 into human subjects, it triggered headaches in every single participant. Among people with a history of migraine, 58% developed full-blown migraine attacks. The biology is real, and it's potent.

The Lundbeck Problem (and Slate's Edge)

Slate isn't the only company chasing PACAP. Danish pharma giant Lundbeck has been developing bocunebart, an anti-PACAP antibody that just posted positive Phase IIb results. In 431 patients who had failed one to four prior preventive treatments, bocunebart significantly reduced monthly migraine days compared to placebo over 12 weeks.

So Lundbeck is ahead on clinical data. Why should anyone care about Slate?

Two words: delivery method.

Bocunebart is an IV infusion. That means patients need to go to a clinic, sit in a chair, and get hooked up to an IV. It's not exactly something you squeeze in between meetings. And there's a telling detail in Lundbeck's story: they actually tested a subcutaneous (under-the-skin) version of bocunebart, and it failed a futility analysis in 2025. They had to scrap the SC arm entirely and focus on IV only.

Slate's SLTE-1009, by contrast, is engineered from the ground up for subcutaneous delivery. It uses half-life extension technology that lets patients inject it at home, potentially monthly or quarterly, instead of trekking to an infusion center. If you've ever compared the convenience of a home pregnancy test to a lab blood draw, you get the idea.

This matters more than you might think. In the CGRP world, the self-injectable options (Aimovig, Ajovy, Emgality) dominate the market while Lundbeck's own IV CGRP drug, Vyepti, plays a distant fourth fiddle. Patients overwhelmingly prefer sticking themselves at home over scheduling infusion appointments. The same dynamic should hold for PACAP drugs.

Of course, there's a catch. Lundbeck's SC failure raises a legitimate question: is subcutaneous delivery fundamentally harder for anti-PACAP antibodies? Was it a Lundbeck-specific problem, or is there something about PACAP blockade that makes SC absorption tricky? Slate is betting it's the former, that better antibody engineering can crack the code. But that's unproven.

Licensed From China, Built for the U.S.

SLTE-1009 wasn't invented in-house. Slate licensed it from DartsBio Pharmaceuticals, a Chinese biotech company based in Guangdong. The specific deal terms (upfront payment, milestones, royalties) haven't been disclosed.

This fits a growing trend of U.S. startups licensing early-stage assets from Chinese biotechs, then developing them for Western markets. It's a model that lets startups move fast without spending years in discovery. The risk? You're building a company around someone else's molecule, and the preclinical data for SLTE-1009 hasn't been publicly detailed.

The Stakes Are Enormous

Migraine isn't a niche condition. It affects over a billion people globally. The CGRP market alone generates billions in annual revenue. And yet roughly half of those patients are still underserved.

If PACAP blockade works, and the early evidence from Lundbeck's trials suggests it can, you're looking at a market that could rival CGRP in size. It's an entirely new pathway for an entirely new patient population. The opportunity is less "incremental improvement" and more "second wave."

But Slate faces real hurdles. Their drug has zero clinical data so far. Phase 1 doesn't start until mid-2026, which means we won't see meaningful efficacy results for years. Other companies have already stumbled on PACAP; Amgen's anti-PAC1 receptor antibody failed, and Lilly stopped its own anti-PACAP program after Phase 2.

What to Watch

The PACAP story comes down to three questions:

Can subcutaneous delivery actually work for PACAP antibodies? Lundbeck couldn't make it happen. Slate claims its half-life extension engineering solves the problem. The Phase 1 data will be the first real test.

Can Slate differentiate from Lundbeck's IV option? If bocunebart reaches the market first as an IV drug, Slate needs to prove that SC convenience isn't just nice to have; it's a clinical and commercial necessity.

How big is the CGRP non-responder population really? The 40–50% failure number gets thrown around a lot, but the definition of "failure" varies. Some patients partially respond. Some just stop taking their meds. Slate needs a clearly defined, reachable patient population that doctors will actually prescribe for.

$130 million is a serious bet on all three answers being favorable. RA Capital and Forbion aren't known for writing checks on vibes: they see something in the data or the engineering that gives them confidence.

For the millions of migraine patients who've tried everything and found nothing, Slate represents something powerful: the possibility that the problem wasn't them, it was the pathway. Now someone's finally going after the other one.

250 Patients Just Changed the FDA's Playbook Forever

For decades, patients with one of the rarest metabolic diseases on earth had exactly one treatment option: an impossibly strict diet. The FDA just approved the first drug that attacks the actual problem, and the ripple effects could reshape how ultra-rare diseases get treated.